SABCS 2021 | 16-gene signature identifies early-stage invasive breast cancer patients who may omit radiotherapy

Corey Speers, MD, PhD, University of Michigan Medicine, Ann Arbor, MI, presents findings of a study using a 16-gene signature (POLAR) to identify early-stage invasive breast cancer patients who may omit radiotherapy. The POLAR genomic signature accurately identified patients with a low risk of locoregional recurrence without significant benefit from adjuvant radiotherapy. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.